Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GRAL vs SHC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SHC Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

SHC Overall Winner 6-Pillar Tally: GRAL 1 – 5 SHC Matrix Metrics: GRAL 4 – 6 SHC

As of Nov 16, 2026, Sotera Health Company (SHC) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas SHC carries 63.1/100 (BUY) at $16.25 (15.3x Forward P/E, 36.8% operating margin).

  • Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile SHC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GRAL vs SHC
GRAL NASDAQ
GRAIL, Inc. Common Stock
Services-Medical Laboratories
$105.60
-8.88% 1D
Market Cap $5.2B
TTM Revenue $167M
Forward P/E 1.1x
Beta / 30D Vol 3.09β · 99% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $132.32 · SMA50: $121.37
SHC NASDAQ Head-to-Head Winner
Sotera Health Company Common Stock
Services-Misc Health & Allied Services, Nec
$16.25
-2.17% 1D
Market Cap $4.7B
TTM Revenue $1.23B
Forward P/E 15.3x
Beta / 30D Vol 0.95β · 44% Vol
Unified Composite Score
63.1 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.9%), weak momentum, RSI 38
RSI-14: 38.1 · SMA20: $17.23 · SMA50: $17.91

6-Pillar Scorecard Institutional Category Breakdown (GRAL 1 – 5 SHC)

Columns: Metric · GRAL · SHC
1. Valuation Multiples GRAL
Forward P/E 1.1x 15.3x
Trailing P/E 1.1x 27.7x
PEG Ratio N/M 1.68x
EV / Revenue 31.6x 3.9x
2. Growth & Scale SHC
Revenue Growth (YoY) +3.7% +4.4%
Earnings Growth (YoY) +0.0% +17.6%
TTM Revenue (USD) $167M $1.23B
Market Cap $5.2B $4.7B
3. Profitability & Quality SHC
Gross Margin 46.7% 54.6%
Operating Margin -332.0% 36.8%
Net Profit Margin -243.8% 14.1%
Return on Equity (ROE) -17.3% 27.0%
4. Balance Sheet & Cash Flow SHC
Cash Generation (TTM) -$312M $584M EBITDA
Cash Flow Margin N/A 47.5% EBITDA Mgn
Net Cash / Leverage $57M Net Debt (0.03x D/E) $2.57 Book/Sh · 27.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SHC
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 93.0% (53rd %ile) 56.1% (6th %ile)
Put/Call OI Skew 0.81x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat SHC
OpEx & R&D Intensity N/A 17.8% of Rev ($219M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GRAL (4) vs SHC (6)
Institutional Metric GRAL SHC Criterion Row Edge
Market Capitalization
Scale
$5.2B $4.7B Larger Scale GRAL
Trailing P/E Ratio
Valuation
1.1x 27.7x Lower Multiple GRAL
Forward P/E Ratio
Valuation
1.1x 15.3x Lower Multiple GRAL
Revenue Growth (YoY)
Growth
+3.7% +4.4% Higher Growth SHC
Operating Margin (TTM)
Profitability
-332.0% 36.8% Higher Margin SHC
Net Profit Margin
Profitability
-243.8% 14.1% Higher Margin SHC
Return on Equity (ROE)
Capital Efficiency
-17.3% 27.0% Higher ROE SHC
52-Week Range Position
Momentum
51% ($42–$166) 47% ($13–$20) Stronger Trend GRAL
Beta / 30D Volatility
Risk Regime
3.09β · 99% Vol 0.95β · 44% Vol Lower Realized Risk SHC
Unified Institutional Score
Composite Signal
54.5 / 100 (HOLD) 63.1 / 100 (BUY) Higher Composite SHC
Trailing 12M Revenue (USD)
Operating Scale
$167M $1.23B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% 54.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 31.6x EV/Rev 1.68x PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$312M ($57M Net Debt (0.03x D/E)) $584M EBITDA ($2.57 Book/Sh · 27.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SHC +1.19 pp
GRAL: -10.36% · SHC: -9.17%
3M Horizon GRAL +64.52 pp
GRAL: +50.96% · SHC: -13.56%
6M Horizon GRAL +70.61 pp
GRAL: +77.03% · SHC: +6.42%
1Y Horizon GRAL +25.42 pp
GRAL: +26.92% · SHC: +1.5%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRAL vs SHC. Trailing 12-month operating profitability (GRAL -332.0% vs SHC 36.8%) and valuation multiples (GRAL 1.1x vs SHC 15.3x Forward P/E) are benchmarked directly in Pillar 4 below.

GRAL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$167M
Gross Margin46.7%
Op. Margin-332.0%
ROE / Fwd P/E-17.3% · 1.1x
SHC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.23B
Gross Margin54.6%
Op. Margin36.8%
ROE / Fwd P/E27.0% · 15.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GRAL BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SHC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 56.1%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GRAL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.2B market capitalization and -332.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SHC Moat Profile High-Margin Pricing Power Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and 36.8% operating margin.
OpEx & R&D Reinvestment 17.8% of Rev ($219M)
90D Engineering Disclosures 0 Published

Investor FAQ GRAL vs SHC Key Questions & Quantitative Answers

As of Nov 16, 2026, Sotera Health Company (SHC) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas SHC carries 63.1/100 (BUY) at $16.25 (15.3x Forward P/E, 36.8% operating margin). Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile SHC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SHC leads the Growth & Scale pillar: GRAL posts +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin), compared with SHC at +4.4% YoY revenue growth and +17.6% YoY earnings growth on $1.23B TTM revenue (54.6% gross margin, 36.8% operating margin). On trailing 12-month operating scale, GRAL generates $167M in USD-normalized revenue versus $1.23B for SHC. In operating R&D and SG&A reinvestment, GRAL deploys N/A (0 90-day corporate R&D disclosures) versus 17.8% of Rev ($219M) (0 disclosures) for SHC.

GRAL screens cheaper on headline valuation multiples. GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin), whereas SHC trades at 15.3x Forward P/E, 27.7x Trailing P/E, 1.68x PEG, and 3.9x EV/Revenue (47.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRAL (-17.3% ROE) versus SHC (27.0% ROE) capital efficiency.

In options market volatility and institutional positioning, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk). By comparison, SHC carries 56.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.95β · 44% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.